CLMT Calumet, Inc

Nasdaq calumet.com


$ 18.51 $ -0.20 (-1.07 %)    

Tuesday, 21-Oct-2025 15:54:40 EDT
QQQ $ 612.20 $ 0.67 (0.11 %)
DIA $ 469.98 $ 2.89 (0.62 %)
SPY $ 672.31 $ 0.82 (0.12 %)
TLT $ 92.01 $ 0.02 (0.02 %)
GLD $ 377.27 $ -9.37 (-2.42 %)
$ 18.78
$ 18.54
$ 18.50 x 100
$ 18.52 x 61
$ 18.18 - $ 18.56
$ 7.68 - $ 23.75
432,452
na
0
$ 1.75
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 calumet-wins-epa-approval-for-small-refinery-exemptions-slashes-rin-liability-by-over-75

Calumet, Inc. (NASDAQ:CLMT) ("Calumet, ""we," "our" or "us") provided an update regarding the r...

 ubs-maintains-neutral-on-calumet-raises-price-target-to-1325

UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $12 to $13.25.

 calumet-extends-shreveport-terminal-financing-arrangement-with-stonebriar-unlocks-80m-proceeds-via-120m-asset-revaluation

Calumet, Inc. (NASDAQ:CLMT) ("Calumet" or the "Company") announced today that it has extended its Shreveport te...

 wells-fargo-maintains-overweight-on-calumet-lowers-price-target-to-21

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $23 to $21.

 calumet-renewables-expansion-is-unlocking-value-analyst

Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.

 b-of-a-securities-initiates-coverage-on-calumet-with-buy-rating-announces-price-target-of-15

B of A Securities analyst Conor Fitzpatrick initiates coverage on Calumet (NASDAQ:CLMT) with a Buy rating and announces Pric...

 calumet-specialty-prods-q1-eps-187-misses-057-estimate-sales-99390m-beat-89144m-estimate

Calumet Specialty Prods (NASDAQ:CLMT) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimat...

 goldman-sachs-maintains-buy-on-calumet-lowers-price-target-to-14

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and lowers the price target from $16 to $14.

 wells-fargo-maintains-overweight-on-calumet-lowers-price-target-to-23

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $28 to $23.

 calumet-reveals-intention-to-nominate-julio-quintana-and-karen-narwold-to-board-wasserstein-debt-opportunities-expresses-support

Jim Carter and Dan Sheets have informed the Board of their decision not to seek re-election and to retire at the end of their t...

 ubs-upgrades-calumet-to-neutral-lowers-price-target-to-12

UBS analyst Manav Gupta upgrades Calumet (NASDAQ:CLMT) from Sell to Neutral and lowers the price target from $15 to $12.

 wells-fargo-maintains-overweight-on-calumet-lowers-price-target-to-28

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $29 to $28.

 hc-wainwright--co-reiterates-buy-on-calumet-maintains-33-price-target

HC Wainwright & Co. analyst Amit Dayal reiterates Calumet (NASDAQ:CLMT) with a Buy and maintains $33 price target.

 calumet-specialty-prods-q4-2024-gaap-eps-047-beats-073-estimate-sales-94950m-beat-92176m-estimate

Calumet Specialty Prods (NASDAQ:CLMT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION